Vaccibody announces the closing of the worldwide license and collaboration agreement with Genentech All antitrust contingencies required to close the agreement with Genentech, regarding the development of individualized neoantigen cancer vaccines, have been satisfied Oslo, Norway, November 06, 2020 – Vaccibody AS, a clinical-stage biopharmaceutical company...
$NEL Hydrogen clearly will benefit from a Biden presidency! If it can establish trading above 20 NOK, the stage looks set for a strong pre christmas rally.
November 4, 2020; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2020 Highlights Novartis granted U.S. FDA approval for Kesimpta® (ofatumumab) in relapsing multiple sclerosis Janssen and European Myeloma Network achieved positive topline results from Phase 3 APOLLO study of daratumumab in relapsed or refractory multiple...
SoftOx, today announced the US Department of Defense (DoD) awarded SoftOx $1.977 million (USD) for research and development of the SoftOx Infection remover (Biofilm Eradicator). Oslo 03.11.2020 The project is a research and development collaboration between SoftOx Solutions AS and leading US and European wound care clinics, focusing on chronic wounds and biofilm...
Look for the stock punching through 200 SMA on good volume
The $GRAF SPAC had a very successfull run into the Velodyne IPO, but since investors have been having a hard time. Can this exciting Lidar pureplay recover?
The Danish Medicines Agency has given its recommendation for further development of the SoftOx inhalation solution for the treatment of respiratory infections, including COVID-19. The SoftOx Inhalation Project aims to develop an inhalation solution for the treatment of respiratory infections. This has the potential to be a breakthrough in the treatment of...
Highlights for Q3 2020 • Annual group sales exceed 100 MNOK for the first time • Gross profit for the Group improved 65% to NOK 26.0 million (Q3 2019: NOK 15.7 million) • ArcticZymes had Q3 sales of NOK 19.5 million growing by 63% (Q3 2019: NOK 12.0 million) • Biotec BetaGlucans had Q3 sales of NOK 11.2 million growing by 7% (Q3 2019: NOK 10.5 million) • Upsides...
Oslo, 19 October 2020: Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer. The results confirm achievement of the primary endpoints of safety and tolerability and indicate encouraging initial signals of long-term...
Enthusiastic trading ahead of Kitrons Q3 report which is scheduled for October 20th
VACCIBODY ENTERS INTO WORLDWIDE LICENSE AND COLLABORATION AGREEMENT WITH GENENTECH, A MEMBER OF THE ROCHE GROUP, TO DEVELOP INDIVIDUALIZED NEOANTIGEN CANCER VACCINES Vaccibody enters into worldwide, exclusive license and collaboration agreement with Genentech to develop VB10.NEO, individualized neoantigen cancer vaccines OCTOBER 1, 2020 VACCIBODY LISTS ON OSLO...
* Norwegian Drug Delivery Platform Biotech operating within the Oslo Cancer Cluster * Notoriously volatile norwegian small cap with large amount of stock held by enthusiastic retail investor crowd. * Ongoing research collaboration with AstraZeneca recently concluded, longs betting on partnership deal incoming. * Stock typically rallies ahead of quarterly reports...
Retail longs caught offguard by huge selloff after the stock went public following its reverse merger with GRAF. Note how hourly RSI set a lower high and other momentum indicators are about to possibly turn bullish.
NEL has become a trader favourite with recent volatility after Nikola was hit by short seller report. Hourly 20 EMA breaking above 100 EMA, often seen as a promising momentum shift indicator. NEL needs to break above support/resistance at about 18 and consolidate to regain a bullish sentiment in the short term. Todays top 20 list show that the Clearstream crowd...
Look for increased trading volume confirming breakout above NOK 94
September 30, 2020 Bitcoin Group SE publishes semi-annual report 2020 - dynamic growth despite challenging environment Sales revenues increase sharply by more than 153% to EUR 6,228 thousand EBITDA more than tripled to EUR 4,177 thousand (previous year: EUR 1,231 thousand) Management confirms all forecasts Herford, September 30, 2020 - Bitcoin Group SE (ISIN...
Quantafuel executed an extremely successfull round of financing after strong newsflow, but is currently trading at last relevant level of support. Note the volume profile in the chart. Investors could try a new long position at this price level, but should have a keen eye on risk management. Or do the safe choice, and wait to see if the stock bounces.
As expected in previous trading idea, NEL falling under important support confirmed the double top sell signal. But NEL is a stock that has experience several huge volatility events in the past, with earlier drops from top to bottom as large as 53 and 58 %. Compared to those the recent drop of 36% seem to not cause any sense of panic among the shareholders at...